Amoun Pharmaceutical Co., one of the largest drugmakers in Egypt, is considering an initial public offering as an alternative to selling the company, three people with knowledge of the matter said. Amoun’s shareholders are considering an IPO after some of the potential bidders for the company dropped out, one of the people said, asking not to be identified as the information is private. The company is still in sale discussions with one private-equity firm, another person said, without disclosing the name of the bidder. Emerging markets-focused private-equity firm Actis LLP is separately considering a pre-IPO investment in the company, two of the people said. The drugmaker’s shareholders have hired Jefferies Group LLC to explore a potential sale, Chief Executive Officer Mohamed Roushdy said in May. The company’s owners include U.S.-based emerging market-focused private-equity arms of Capital Group Inc., Concord International Investments LP, and the Rohatyn Group, which bought Citigroup Inc.’s buyout business last year. Bloomberg